Previous close | 14.83 |
Open | 14.83 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 945.00 |
Expiry date | 2024-11-15 |
Day's range | 14.83 - 14.83 |
Contract range | N/A |
Volume | |
Open interest | N/A |
We recently compiled a list of 10 High Growth NASDAQ Stocks That Are Profitable in 2024. In this article, we will look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the high-growth NASDAQ stocks that are profitable. Will the Bull Market Continue as We Enter the Earnings Season? Malcolm Ethridge, Capital Area Planning Group managing […]
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.
The heavy selling pressure might have exhausted for Regeneron (REGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.